Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions

0 avis

Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions

Archive ouverte

Edité par CCSD ; Karger -

International audience. Lung cancer is one of the most common solid cancers and represents the leading cause of cancer death worldwide. Over the last decade, research on the epithelial-mesenchymal transition (EMT) in lung cancer has gained increasing attention. Here, we review clinical and histological features of non-small-cell lung cancer associated with EMT. We then aimed to establish potential clinical implications of EMT in current therapeutic options, including surgery, radiation, targeted therapy against oncogenic drivers, and immunotherapy.

Langue: en

Indexation

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Hypoxia in Lung Cancer Management: A Translational Approach

Archive ouverte | Ancel, Julien | CCSD

International audience. Lung cancer represents the first cause of death by cancer worldwide and remains a challenging public health issue. Hypoxia, as a relevant biomarker, has raised high expectations for clinical ...

Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors

Archive ouverte | Ancel, Julien | CCSD

International audience. Lung cancer remains the first cause of cancer-related death despite many therapeutic innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily practice at late...

Epithelial to mesenchymal transition to predict immune resistance in non-small cell lung cancer

Archive ouverte | Ancel, Julien | CCSD

International audience. IntroductionLung cancer remains the main cause of death worldwide, despite significant clinical benefit by immunotherapy (IO). Programmed Death-Ligand 1 (PD-L1) used as a biomarker is insuffi...

Chargement des enrichissements...